Header Logo

Connection

DOV KADMON to Immunotherapy

Back to Details
This is a "connection" page, showing publications DOV KADMON has written about Immunotherapy.
DOV KADMON
Connection Strength
0.148
Immunotherapy
  1. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. 2014 Apr; 32(2):235-242.
    View in: PubMed
    Score: 0.069
  2. BCG and the treatment of superficial bladder cancer. DICP. 1991 Dec; 25(12):1355-67.
    View in: PubMed
    Score: 0.062
  3. Therapeutic targets for metastatic prostate cancer. Curr Drug Targets. 2003 Apr; 4(3):251-61.
    View in: PubMed
    Score: 0.009
  4. Immunotherapy of superficial bladder cancer. J Urol. 1982 Nov; 128(5):891-4.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.